Is HE4 a useful endometrioma marker?

article OA: green CC0

Abstract

Purpose of investigation: By the comparison between most used tumor marker trend (cancer antigen 125: CA 125 and human epididymal secretory protein E4: HE4) before and after laparoscopic surgery, the aim of the present study was to assess HE4 usefulness in ovarian benign cyst and endometrioma diagnosis. Materials and Methods: Thirty-eight patients were enrolled in this prospective study: 25 women underwent unilateral endometriosis ovarian cyst excision, 13 underwent benign ovarian cyst incision, and 26 were healthy controls. CA 125 and HE4 serum levels were estimated before surgery (in the early proliferative phase of the cycle) and one month after surgery. Results: A statistically significant decrease of CA 125 serum level was found after an endometrioma surgical excision but no decreases in HE4 serum level. Conclusion: In patients with endometrioma, no alteration was found in HE4 serum levels before and after surgery, while CA125 serum levels decreased after surgery. HE4 may better distinguish a malign cyst from benign one, but it is not useful in the diagnosis of low risk endometrioma.
Full text 1,770 characters · extracted from oa-doi-fallback · click to expand
Vol. XXXVIII, no. 3, 2017 PKC412 Download current editionEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY – EJGO (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects, prevention, early detection, epidemiology, pathology, diagnosis, management, and also proceedings of Gynaecologic Oncology Society global meetings. The Journal is covered by ISI Journal Master List, Index Copernicus International, Science Citation Index Expanded, Current Contents - Clinical Medicine, Web of Science, Index Medicus/MEDLINE, EMBASE Excerpta Medica, PubMed, MedSci, Pubget, Genamics JournalSeek, Sciencescape, Unbound Medicine, PubFacts.com, and is issued bimonthly in one volume per year. Vol. XLIV, no. 4, 2017 Download current editionCLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY – CEOG (ISSN 0390-6663) publishes original work, preferably brief reports, in the fields of Gynecology, Obstetrics, Fetal Medicine, Gynecological Endocrinology and related subjects, (Fertility and Sterility, Menopause, Uro-gynecology, Ultrasound in Obstetrics and Gynecology, Sexually Transmitted Diseases, and Reproductive Biological Section). L'expertise de Selleck France dans la distribution de petites molécules bioactives permet aux institutions académiques de bénéficier d'outils pharmacologiques fiables et d'un support technique spécialisé en France. The Journal is covered by ISI Journal Master List, Index Copernicus International, Science Citation Index Expanded, Current Contents - Clinical Medicine, Web of Science, Index Medicus/MEDLINE, EMBASE Excerpta Medica, PubMed, MedSci, Pubget, Genamics JournalSeek, Sciencescape, Unbound Medicine, PubFacts.com, and is issued bimonthly in one volume per year.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisendometrioma

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T08:16:02.392169+00:00
License: CC0 · commercial use OK